BARNADAS MOLINS, AGUSTI FGS
abarnadasm@santpau.cat
Escuin Borras, Daniel IR
Menendez Cuervo, Dulce Maria IR
Alfonso Ruiz, Rosa IR
Fisas Masferrer, David IR
Pich Martinez, Olga IR
Pallares Curto, Maria Cinta FGS
Lopez Pousa, Antonio FGS
Maroto Rey, Jose Pablo FGS
Calvo Verges, Nuria FGS
Martin Richard, Marta FGS
Majem Tarruella, Margarita FGS
Gallego Rubio, Oscar Salvador FGS
Paez Lopez-bravo, David FGS
Tibau I Martorell, Ariadna FGS
Ramon Y Cajal Asensio, Teresa FGS
Sebio Garcia, Ana FGS
Bell Ramirez, Olga Lidia IR
Ribas Carbonell, Romina IR
Martin Lorente, Cristina FGS
TobeÑa Puyal, Maria FGS
Garcia Belinchon, Maria De La Merce IR
Castells Tello, Diana IR
Llobet Busquets, Mireia IR
Arqueros NuÑez, Cristina FGS
Lavernia Rosell, Laia IR
Llado Jordan, Gina IR
Serra Lopez, Jorgina IR
Casanova Bombardo, Claudia IR
Roca Sola, Marc IR
Gisbert Beamud, Alexandra IR
Virgili Manrique, Anna Cristina IR
Buxo Orra, Elvira FGS
Barba Joaquin, Andres IR
Roca Gimeno, Llara IR
Galceran Gallagher, Sara IR
Andres Granyo, Marta IR
Saavedra Bandera, Eduard IR
Tijeras Perez, Sandra IR
Anglada T., Repulles J., Espinal A., LaBarge M.A., Stampfer M.R., Genesca A., Martin M. (2019) Delayed γH2AX foci disappearance in mammary epithelial cells from aged women reveals an age-associated DNA repair defect. AGING-US, 11 (5), 1501-1509.
IF: 4,8310
Aparicio J., Sanchez-Munoz A., Ochenduszko S., Guma J., Fernandez-Aramburo A., Garcia Del Muro X., Quiroga V., Sastre J., Alonso-Gordoa T., Sagastibelza N., Maroto P., Gomez de Liano A., Vazquez S., Diz P., Duran I., Domenech M., Pinto A., Hernandez A., Gonzalez-Billalabeitia E., Terrasa J. (2019) Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. J UROLOGY, 202 (4), 742-747.
IF: 5,9250
Arranz M.J., Gonzalez-Rodriguez A., Perez-Blanco J., Penades R., Gutierrez B., Ibanez L., Arias B., Brunet M., Cervilla J., Salazar J., Catalan R. (2019) A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. TRANSL PSYCHIAT, 9 (1), -.
IF: 5,2800
Arroyo-Solera I., Pavon M.A., Leon X., Lopez M., Gallardo A., Cespedes M.V., Casanova I., Pallares V., Lopez-Pousa A., Mangues M.A., Barnadas A., Quer M., Mangues R. (2019) Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma. HEAD NECK-J SCI SPEC, 41 (2), 429-439.
IF: 2,5380
Ballesteros M., Montero N., Lopez-Pousa A., Urrutia G., Sola I., Rada G., Pardo-Hernandez H., Bonfill X. (2019) Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas. CLIN TRANSL ONCOL, 21 (10), 1398-1412.
IF: 2,7370
Blancas I., Aguirre E., Morales S., Gonzalvez M.L., Servitja S., Diaz N., del Barco S., Barnadas A., Margeli M., Garcia Carbonero I., Llombart A. (2019) Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. CLIN TRANSL ONCOL, 21 (4), 459-466.
IF: 2,7370
Calderon C., Carmona-Bayonas A., Beato C., Ghanem I., Hernandez R., Majem M., Rosa Diaz A., Higuera O., Mut Lloret M., Jimenez-Fonseca P. (2019) Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer. CLIN TRANSL ONCOL, 21 (5), 687-691.
IF: 2,7370
Calderon C., Carmona-Bayonas A., Jara C., Beato C., Mediano M., Ramon y Cajal T., Carmen Soriano M., Jimenez-Fonseca P. (2019) Emotional functioning to screen for psychological distress in breast and colorectal cancer patients prior to adjuvant treatment initiation. EUR J CANCER CARE, 28 (3), -.
IF: 2,1610
Calderon C., Ferrando P.J., Lorenzo-Seva U., Higuera O., Ramon y Cajal T., Rogado J., Mut-Lloret M., Rodriguez-Capote A., Jara C., Jimenez-Fonseca P. (2019) Validity and Reliability of the Decision Regret Scale in Cancer Patients Receiving Adjuvant Chemotherapy. J PAIN SYMPTOM MANAG, 57 (4), 828-834.
IF: 3,0770
Carles J., Gallardo E., Domenech M., Font A., Bellmunt J., Figols M., Mellado B., Saez M.I., Suarez C., Mendez M.J., Maroto P., Luque R., de Portugal T., Aldabo R., Bonfill T., Morales-Barrera R., Garcia J., Macia S., Maldonado X., Foro P. (2019) Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. INT J RADIAT ONCOL, 103 (2), 344-352.
IF: 5,8590
Carmona-Bayonas A., Jimenez-Fonseca P., Garrido M., Custodio A., Hernandez R., Lacalle A., Cano J.M., Aguado G., Martinez de Castro E., Alvarez Mancenido F., Macias I., Visa L., Martin Richard M., Mangas M., Sanchez Canovas M., Longo F., Iglesias Rey L., Martinez Lago N., Martin Carnicero A., Sanchez A., Azkarate A., Limon M.L., Hernandez Perez C., Ramchandani A., Pimentel P., Cerda P., Serrano R., Gil-Negrete A., Marin M., Hurtado A., Sanchez Bayona R., Gallego J. (2019) Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. THROMB HAEMOSTASIS, 119 (11), 1849-1859.
IF: 4,3790
Casanova I., Unzueta U., Arroyo-Solera I., Cespedes M.V., Villaverde A., Mangues R., Vazquez E. (2019) Protein-driven nanomedicines in oncotherapy. CURR OPIN PHARMACOL, 47 (), 1-7.
IF: 4,8070
Corral J., Majem M., Rodriguez-Abreu D., Carcereny E., Cortes A.A., Llorente M., Lopez Picazo J.M., Garcia Y., Domine M., Lopez Criado M.P. (2019) Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. CLIN TRANSL ONCOL, 21 (9), 1270-1279.
IF: 2,7370
de las Penas R., Majem M., Perez-Altozano J., Virizuela J.A., Cancer E., Diz P., Donnay O., Hurtado A., Jimenez-Fonseca P., Ocon M.J. (2019) SEOM clinical guidelines on nutrition in cancer patients (2018). CLIN TRANSL ONCOL, 21 (1), 87-93.
IF: 2,7370
Draganov M., Arranz M.J., Salazar J., de Diego-Adelino J., Gallego-Fabrega C., Jubero M., Carceller-Sindreu M., Portella M.J. (2019) Association study of polymorphisms within inflammatory genes and methylation status in treatment response in major depression. EUR PSYCHIAT, 60 (), 7-13.
IF: 4,4640
Fernandez-Martos C., Pericay C., Losa F., Garcia-Carbonero R., Layos L., Rodriguez-Salas N., Martin-Richard M., Alonso-Orduna V., Vera R., Gallego J., Capdevila J., Salud A., Nogue M., Maurel J., Guash I., Montagut C., Lopez C., Macias I., Jain R.K., Garcia-Albeniz X. (2019) Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. JAMA ONCOL, 5 (11), 1566-1573.
IF: 24,7990
Font R., Espinas J.A., Barnadas A., Izquierdo A., Galceran J., Saladie F., Marcos-Gragera R., Torrent A., Manchon-Walsh P., Borras J.M. (2019) Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. BREAST CANCER RES TR, (), -.
IF: 3,8310
Garcia Y.G., De Juan Ferre A., Mendiola C., Barretina-Ginesta M.-P., Gaba Garcia L., Santaballa Bertran A., Bover Barcelo I., Gil-Martin M., Manzano A., Perez M.J.R., Romeo Marin M., Arqueros Nunez C., Garcia-Martinez E., Gonzalez Martin A. (2019) Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. INT J GYNECOL CANCER, 29 (6), 1050-1056.
IF: 2,0950
Garrido P., Vinolas N., Isla D., Provencio M., Majem M., Artal A., Carcereny E., Garcia Campelo R., Lianes P., De La Penas R., Felip E. (2019) Lung cancer in Spanish women: The WORLD07 project. EUR J CANCER CARE, 28 (1), -.
IF: 2,1610
Gomez-Espana M.A., Gallego J., Gonzalez-Flores E., Maurel J., Paez D., Sastre J., Aparicio J., Benavides M., Feliu J., Vera R. (2019) SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLIN TRANSL ONCOL, 21 (1), 46-54.
IF: 2,7370
Gonzalez del Alba A., De Velasco G., Lainez N., Maroto P., Morales-Barrera R., Munoz-Langa J., Perez-Valderrama B., Basterretxea L., Caballero C., Vazquez S. (2019) SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). CLIN TRANSL ONCOL, 21 (1), 64-74.
IF: 2,7370
Gonzalez-Bermudez L., Anglada T., Genesca A., Martin M., Terradas M. (2019) Identification of reference genes for RT-qPCR data normalisation in aging studies. SCI REP-UK, 9 (1), 13970-.
IF: 3,9980
Gravalos C., Sanmartin O., Gurpide A., Espana A., Majem M., Suh Oh H.J., Aragon I., Segura S., Beato C., Botella R. (2019) Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. CLIN TRANSL ONCOL, 21 (5), 556-571.
IF: 2,7370
Grothey A., Yaeger R., Paez D., Tabernero J., Taieb J., Yoshino T., Groc M., Vedovato J., Chetaille E., Van Cutsem E. (2019) ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). ANN ONCOL, 30 (), iv109-.
IF: 18,2740
Herbst R.S., Baas P., Perez-Gracia J.L., Felip E., Kim D.-W., Han J.-Y., Molina J.R., Kim J.-H., Dubos Arvis C., Ahn M.-J., Majem M., Fidler M.J., Surmont V., de Castro G., Garrido M., Shentu Y., Emancipator K., Samkari A., Jensen E.H., Lubiniecki G.M., Garon E.B. (2019) Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial. ANN ONCOL, 30 (2), 281-289.
IF: 18,2740
Hernandez R., Calderon C., Carmona-Bayonas A., Rodriguez Capote A., Jara C., Padilla Alvarez A., Gomez-Camacho M.L.N., Beato C., Castelo B., Majem M., Munoz M.D.M., Ivars A., Mangas-Izquierdo M., Rogado-Revuelta J., Jimenez-Fonseca P. (2019) Differences in coping strategies among young adults and the elderly with cancer. PSYCHOGERIATRICS, 19 (5), 426-434.
IF: 1,7500
Judson I., Morden J.P., Kilburn L., Leahy M., Benson C., Bhadri V., Campbell-Hewson Q., Cubedo R., Dangoor A., Fox L., Hennig I., Jarman K., Joubert W., Kernaghan S., Lopez Pousa A., McNeil C., Seddon B., Snowdon C., Tattersall M., Toms C., Martinez Trufero J., Bliss J.M. (2019) Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. LANCET ONCOL, 20 (7), 1023-1034.
IF: 33,7520
Majem M., Juan O., Insa A., Reguart N., Trigo J.M., Carcereny E., Garcia-Campelo R., Garcia Y., Guirado M., Provencio M. (2019) SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). CLIN TRANSL ONCOL, 21 (1), 3-17.
IF: 2,7370
Marin-Aguilera M., Reig O., Mila-Guasch M., Font A., Domenech M., Rodriguez-Vida A., Carles J., Suarez C., del Alba A.G., Jimenez N., Victoria I., Sala-Gonzalez N., Ribal M.J., Lopez S., Etxaniz O., Anguera G., Maroto P., Fernandez P.L., Prat A., Mellado B. (2019) The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. INT J CANCER, 145 (7), 1970-1981.
IF: 5,1450
Martin-Broto J., Stacchiotti S., Lopez-Pousa A., Redondo A., Bernabeu D., de Alava E., Casali P.G., Italiano A., Gutierrez A., Moura D.S., Pena-Chilet M., Diaz-Martin J., Biscuola M., Taron M., Collini P., Ranchere-Vince D., Garcia Del Muro X., Grignani G., Dumont S., Martinez-Trufero J., Palmerini E., Hindi N., Sebio A., Dopazo J., Dei Tos A.P., LeCesne A., Blay J.-Y., Cruz J. (2019) Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. LANCET ONCOL, 20 (1), 134-144.
IF: 33,7520
Martin-Broto J., Hindi N., Cruz J., Martinez-Trufero J., Valverde C., De Sande L.M., Sala A., Bellido L., De Juan A., Rubio-Casadevall J., Diaz-Beveridge R., Cubedo R., Tendero O., Salinas D., Gracia I., Ramos R., Bague S., Gutierrez A., Duran-Moreno J., Lopez-Pousa A. (2019) Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). ONCOLOGIST, 24 (6), e338-e346.
IF: 5,0250
Paez D., Tobena M., Fernandez-Plana J., Sebio A., Virgili A.C., Cirera L., Barnadas A., Riera P., Sullivan I., Salazar J. (2019) Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. BRIT J CANCER, 120 (2), 190-195.
IF: 5,7910
Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., Schmutzler R.K., Rhiem K., Izatt L., Tripathi V., Teixeira M.R., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Helderman van den Enden A.T.J.M., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A. (2019) Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. EUR UROL, 76 (6), 831-842.
IF: 17,9470
Pavon M.A., Arroyo-Solera I., Leon X., Tellez-Gabriel M., Viros D., Gallardo A., Cespedes M.V., Casanova I., Lopez-Pousa A., Barnadas A., Quer M., Mangues R. (2019) The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes. HEAD NECK-J SCI SPEC, 41 (6), 1830-1845.
IF: 2,5380
Saleh R.R., Majeed H., Tibau A., Booth C.M., Amir E. (2019) Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. CANCER-AM CANCER SOC, 125 (22), 4069-4075.
IF: 5,7420
Serrano C., Garcia-del-Muro X., Valverde C., Sebio A., Duran J., Manzano A., Pajares I., Hindi N., Landolfi S., Jimenez L., Rubio-Casadevall J., Estival A., Lavernia J., Safont M.J., Pericay C., Diaz-Beveridge R., Martinez-Marin V., Vicente-Baz D., Vivancos A., Hernandez-Losa J., Arribas J., Carles J. (2019) Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. ONCOLOGIST, 24 (5), 680-687.
IF: 5,0250
Shepshelovich D., Tibau A., Goldvaser H., Ocana A., Seruga B., Amir E. (2019) Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. MAYO CLIN PROC, 94 (1), 74-83.
IF: 6,9420
Stacchiotti S., Ferrari S., Redondo A., Hindi-Muniz N., Palmerini E., Vaz Salgado M.A., Frezza A.M., Casali P.G., Gutierrez A., Lopez-Pousa A., Grignani G., Italiano A., LeCesne A., Dumont S., Blay J.Y., Penel N., Bernabeu D., de Alava E., Karanian M., Morosi C., Brich S., Dagrada G.P., Vallacchi V., Castelli C., Brenca M., Racanelli D., Maestro R., Collini P., Cruz J., Martin-Broto J. (2019) Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. LANCET ONCOL, 20 (9), 1252-1262.
IF: 33,7520
Sullivan I., Riera P., Andres M., Altes A., Majem M., Blanco R., Capdevila L., Barba A., Barnadas A., Salazar J. (2019) Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. ANGIOGENESIS, 22 (3), 433-440.
IF: 9,7800
Villatoro S., Mayo-de-las-Casas C., Jordana-Ariza N., Viteri-Ramirez S., Garzon-Ibanez M., Moya-Horno I., Garcia-Pelaez B., Gonzalez-Cao M., Malapelle U., Balada-Bel A., Martinez-Bueno A., Campos R., Reguart N., Majem M., Blanco R., Blasco A., Catalan M.J., Gonzalez X., Troncone G., Karachaliou N., Rosell R., Molina-Vila M.A. (2019) Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. MOL ONCOL, 13 (12), 2633-2645.
IF: 6,5740
Alonso V., Escudero P., Fernandez-Martos C., Salud A., Mendez M., Gallego J., Rodriguez J.-R., Martin-Richard M., Fernandez-Plana J., Manzano H., Mendez J.-C., Zanui M., Falco E., Gil-Raga M., Rojo F., Cuatrecasas M., Feliu J., Garcia-Albeniz X., Maurel J. (2018) Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. NEOPLASIA, 20 (7), 678-686.
IF: 3,8370
Anguera G., Majem M. (2018) BRAF inhibitors in metastatic non-small cell lung cancer. J THORAC DIS, 10 (2), 589-592.
IF: 2,0270
Arriola E., Garcia Gomez R., Diz P., Majem M., Martinez Aguillo M., Valdivia J., Paredes A., Sanchez-Torres J.M., Peralta Munoz S., Barneto I., Gutierrez V., Andrade Santiago J.M., Aparisi F., Isla D., Ponce S., Vicente Baz D., Artal A., Amador M., Provencio M. (2018) Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC CANCER, 18 (1), -.
IF: 2,9330
Balana C., Estival A., Teruel I., Hardy-Werbin M., Sepulveda J., Pineda E., Martinez-Garcia M., Gallego O., Luque R., Gil-Gil M., Mesia C., Del Barco S., Herrero A., Berrocal A., Perez-Segura P., de Las Penas R., Marruecos J., Fuentes R., Reynes G., Velarde J.M., Cardona A., Verger E., Panciroli C., Villa S. (2018) Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. CLIN TRANSL ONCOL, 20 (12), 1529-1537.
IF: 2,4410
Barnadas A., Algara M., Cordoba O., Casas A., Gonzalez M., Marzo M., Montero A., Munoz M., Ruiz A., Santolaya F., Fernandez T. (2018) Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). CLIN TRANSL ONCOL, 20 (6), 687-694.
IF: 2,4410
Carles J., Mendez M.J., Pinto A., Saez M.I., Arranz J.A., Maroto P., Lopez-Criado P., Mellado B., Donas J.G., Hernando S., Leon L., Del Alba A.G., Lainez N., Esteban E., Reynes G., Perez-Gracia J.L., Germa J.R., Lopez-Brea M., Perez-Valderrama B., Moretones C., Castellano D. (2018) Radium-223 international early access program: Results from the Spanish subset. FUTURE ONCOL, 14 (1), 41-50.
IF: 2,2790
Casali P.G., Abecassis N., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Brodowicz T., Broto J.M., Buonadonna A., De Alava E., Dei Tos A.P., Del Muro X.G., Dileo P., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Ferrari S., Frezza A.M., Gasperoni S., Gelderblom H., Gil T., Grignani G., Gronchi A., Haas R.L., Hannu A., Hassan B., Hohenberger P., Issels R., Joensuu H., Jones R.L., Judson I., Jutte P., Kaal S., Kasper B., Kopeckova K., Krakorova D.A., Le Cesne A., Lugowska I., Merimsky O., Montemurro M., Pantaleo M.A., Piana R., Picci P., Piperno-Neumann S., Pousa A.L., Reichardt P., Robinson M.H., Rutkowski P., Safwat A.A., Schoffski P., Sleijfer S., Stacchiotti S., Sundby Hall K., Unk M., Van Coevorden F., Van der Graaf W., Whelan J., Wardelmann E., Zaikova O., Blay J.Y. (2018) Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 29 (4), iv68-iv78.
IF: 14,1960
Casali P.G., Abecassis N., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Brodowicz T., Broto J.M., Buonadonna A., De Alava E., Dei Tos A.P., Del Muro X.G., Dileo P., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Ferrari S., Frezza A.M., Gasperoni S., Gelderblom H., Gil T., Grignani G., Gronchi A., Haas R.L., Hannu A., Hassan B., Hohenberger P., Issels R., Joensuu H., Jones R.L., Judson I., Jutte P., Kaal S., Kasper B., Kopeckova K., Krakorova D.A., Le Cesne A., Lugowska I., Merimsky O., Montemurro M., Pantaleo M.A., Piana R., Picci P., Piperno-Neumann S., Pousa A.L., Reichardt P., Robinson M.H., Rutkowski P., Safwat A.A., Schoffski P., Sleijfer S., Stacchiotti S., Sundby Hall K., Unk M., Van Coevorden F., Van der Graaf W., Whelan J., Wardelmann E., Zaikova O., Blay J.Y. (2018) Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 29 (4), iv51-iv67.
IF: 14,1960
Casali P.G., Bielack S., Abecassis N., Aro H.T., Bauer S., Biagini R., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Brennan B., Brodowicz T., Broto J.M., Brugieres L., Buonadonna A., De Alava E., Dei Tos A.P., Del Muro X.G., Dileo P., Dhooge C., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Ferrari S., Frezza A.M., Gaspar N., Gasperoni S., Gelderblom H., Gil T., Grignani G., Gronchi A., Haas R.L., Hassan B., Hecker-Nolting S., Hohenberger P., Issels R., Joensuu H., Jones R.L., Judson I., Jutte P., Kaal S., Kager L., Kasper B., Kopeckova K., Krakorova D.A., Ladenstein R., Le Cesne A., Lugowska I., Merimsky O., Montemurro M., Morland B., Pantaleo M.A., Piana R., Picci P., Piperno-Neumann S., Pousa A.L., Reichardt P., Robinson M.H., Rutkowski P., Safwat A.A., Schoffski P., Sleijfer S., Stacchiotti S., Strauss S.J., Sundby Hall K., Unk M., Van Coevorden F., van der Graaf W.T.A., Whelan J., Wardelmann E., Zaikova O., Blay J.Y. (2018) Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 29 (4), iv79-iv95.
IF: 14,1960
Castellano D., Maroto J.P., Espinosa E., Grande E., Bolos M., Llinares J., Esteban E., Gonzalez del Alba A., Climent M.A., Arranz J., Mendez M.J., Fernandez Parra E., Anton-Aparicio L., Bayona C., Gallegos I., Gallardo E., Samaniego L., Garcia Donas J. (2018) Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. EXPERT OPIN DRUG SAF, 17 (6), 573-579.
IF: 3,2200
Cespedes M.V., Unzueta U., Avino A., Gallardo A., Alamo P., Sala R., Sanchez-Chardi A., Casanova I., Mangues M.A., Lopez-Pousa A., Eritja R., Villaverde A., Vazquez E., Mangues R. (2018) Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO MOL MED, 10 (10), -.
IF: 10,6240
Del Carpio Huerta L., Virgili Manrique A.C., Szafranska J., Martin-Richard M., Paez Lopez-Bravo D., Sebio Garcia A., Espinosa Mariscal I., Gomila Pons P., Andres Granyo M., Barba Joaquin A., Barnadas Molins A., Tobena Puyal M. (2018) Brain metastases in colorectal cancer: prognostic factors and survival analysis. INT J COLORECTAL DIS, 33 (11), 1517-1523.
IF: 2,6410
Echavarria I., Lopez-Tarruella S., Picornell A., Garcia-Saenz J.A., Jerez Y., Hoadley K., Gomez H.L., Moreno F., Monte-Millan M.D., Marquez-Rodas I., Alvarez E., Ramos-Medina R., Gayarre J., Massarrah T., Ocana I., Cebollero M., Fuentes H., Barnadas A., Ballesteros A.I., Bohn U., Perou C.M., Martin M. (2018) Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification. CLIN CANCER RES, 24 (8), 1845-1852.
IF: 8,9110
Gallardo A., Garcia-Valdecasas B., Murata P., Teran R., Lopez L., Barnadas A., Lerma E. (2018) Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. BREAST CANCER RES TR, 167 (1), 31-37.
IF: 3,4710
Garcia Del Muro X., Maurel J., Martinez Trufero J., Lavernia J., Lopez Pousa A., de Las Penas R., Cubedo R., Berros J.P., Casado Herraez A., de Juan A., Martin Broto J. (2018) Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. INVEST NEW DRUG, 36 (3), 468-475.
IF: 2,6630
Garrido P., Aldaz A., Vera R., Calleja M.A., de Alava E., Martin M., Matias-Guiu X., Palacios J. (2018) Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. CLIN TRANSL ONCOL, 20 (4), 443-447.
IF: 2,4410
Gonzalez-Cao M., Mayo De Las Casas C., Jordana Ariza N., Manzano J.L., Molina-Vila M.A., Soriano V., Puertolas T., Balada A., Soria A., Majem M., Montagut C., Munoz E., Rodriguez-Abreu D., Perez E., Garcia A., Cortes J., Drozdowskyj A., Karachaliou N., Rosell R. (2018) Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. MELANOMA RES, 28 (3), 195-203.
IF: 2,3810
Jimenez-Fonseca P., Calderon C., Hernandez R., Ramon Y Cajal T., Mut M., Ramchandani A., Donnay O., Carmona-Bayonas A. (2018) Factors associated with anxiety and depression in cancer patients prior to initiating adjuvant therapy. CLIN TRANSL ONCOL, 20 (11), 1408-1415.
IF: 2,4410
Maio M., Lewis K., Demidov L., Mandala M., Bondarenko I., Ascierto P.A., Herbert C., Mackiewicz A., Rutkowski P., Guminski A., Goodman G.R., Simmons B., Ye C., Yan Y., Schadendorf D., Cinat G., Fein L.E., Brown M., Guminski A., Haydon A., Khattak A., McNeil C., Parente P., Power J., Roberts-Thomson R., Sandhu S., Underhill C., Varma S., Berger T., Awada A., Blockx N., Buyse V., Mebis J., Franke F.A., Jobim de Azevedo S., Silva Lazaretti N., Jamal R., Mihalcioiu C., Petrella T., Savage K., Song X., Wong R., Dabelic N., Plestina S., Vojnovic Z., Arenberger P., Kocak I., Krajsova I., Kubala E., Melichar B., Vantuchova Y., Putnik K., Dreno B., Dutriaux C., Grob J.-J., Joly P., Lacour J.-P., Meyer N., Mortier L., Thomas L., Fluck M., Gambichler T., Hassel J., Hauschild A., Schadendorf D., Donnellan P., McCaffrey J., Power D., Ariad S., Bar-Sela G., Hendler D., Ron I., Schachter J., Ascierto P., Berruti A., Bianchi L., Chiarion Sileni V., Cognetti F., Danielli R., Di Giacomo A.M., Gianni L., Goldhirsch A., Guida M., Maio M., Mandala M., Marchetti P., Queirolo P., Santoro A., Kapiteijn E., Mackiewicz A., Rutkowski P., Ferreira P., Demidov L., Gafton G., Makarova Y., Andric Z., Babovic N., Jovanovic D., Kandolf Sekulovic L., Cohen G., Dreosti L., Vorobiof D., Curiel Garcia M.T., Diaz Beveridge R., Majem Tarruella M., Marquez Rodas I., Puliats Rodriguez J.-M., Rueda Dominguez A., Maroti M., Papworth K., Michielin O., Bondarenko I., Brown E., Corrie P., Harries M., Herbert C., Kumar S., Martin-Clavijo A., Middleton M., Patel P., Talbot T., Agarwala S., Chapman P., Conry R., Doolittle G., Gangadhar T., Hallmeyer S., Hamid O., Hernandez-Aya L., Johnson D., Kass F., Kolevska T., Lewis K., Lunin S., Salama A., Sikic B., Somer B., Spigel D., Whitman E. (2018) Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. LANCET ONCOL, 19 (4), 510-520.
IF: 35,3860
Maroto P., Anguera G., Martin C. (2018) Long-term toxicity of the treatment for germ cell-cancer. A review. CRIT REV ONCOL HEMAT, 121 (), 62-67.
IF: 5,0120
Martin-Liberal J., Lopez-Pousa A., Martinez-Trufero J., Martin-Broto J., Cubedo R., Lavernia J., Redondo A., Lopez-Martin J.A., Mulet-Margalef N., Sanjuan X., Tirado O.M., Garcia-del-Muro X. (2018) Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. TARGET ONCOL, 13 (1), 81-87.
IF: 3,6830
Maurel J., Sanchez-Cabus S., Laquente B., Gaba L., Visa L., Fabregat J., Poves I., Rosello S., Diaz-Beveridge R., Martin-Richard M., Rodriguez J., Sabater L., Conill C., Cambray M., Reig A., Ayuso J.R., Valls C., Ferrandez A., Bombi J.A., Gines A., Garcia-Albeniz X., Fernandez-Cruz L. (2018) Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). CANCER CHEMOTH PHARM, 82 (6), 935-943.
IF: 3,0080
Pal S.K., Rosenberg J.E., Hoffman-Censits J.H., Berger R., Quinn D.I., Galsky M.D., Wolf J., Dittrich C., Keam B., Delord J.-P., Schellens J.H.M., Gravis G., Medioni J., Maroto P., Sriuranpong V., Charoentum C., Burris H.A., Grunwald V., Petrylak D., Vaishampayan U., Gez E., De Giorgi U., Lee J.-L., Voortman J., Gupta S., Sharma S., Mortazavi A., Vaughn D.J., Isaacs R., Parker K., Chen X., Yu K., Porter D., Porta D.G., Bajorin D.F. (2018) Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. CANCER DISCOV, 8 (7), 812-821.
IF: 26,3700
Pasquali S., Colombo C., Pizzamiglio S., Verderio P., Callegaro D., Stacchiotti S., Martin Broto J., Lopez-Pousa A., Ferrari S., Poveda A., De Paoli A., Quagliuolo V., Jurado J.C., Comandone A., Grignani G., De Sanctis R., Palassini E., Llomboart-Bosch A., Dei Tos A.P., Casali P.G., Picci P., Gronchi A. (2018) High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. EUR J CANCER, 93 (), 28-36.
IF: 6,6800
Pastor M., Lopez Pousa A., Del Barco E., Perez Segura P., Astorga B.G., Castelo B., Bonfill T., Martinez Trufero J., Grau J.J., Mesia R. (2018) SEOM clinical guideline in nasopharynx cancer (2017). CLIN TRANSL ONCOL, 20 (1), 84-88.
IF: 2,4410
Paumard-Hernandez B., Calvete O., Inglada Perez L., Tejero H., Al-Shahrour F., Pita G., Barroso A., Carlos Trivino J., Urioste M., Valverde C., Gonzalez Billalabeitia E., Quiroga V., Francisco Rodriguez Moreno J., Fernandez Aramburo A., Lopez C., Maroto P., Sastre J., Jose Juan Fita M., Duran I., Lorenzo-Lorenzo I., Iranzo P., Garcia del Muro X., Ros S., Zambrana F., Maria Autran A., Benitez J. (2018) Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. INT J CANCER, 143 (8), 1954-1962.
IF: 4,9820
Riera P., Virgili A.C., Salazar J., Sebio A., Tobena M., Sullivan I., Paez D. (2018) Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. PHARMACOGENOMICS J, 18 (4), 556-564.
IF: 3,5030
Riera P., Salazar J., Virgili A.C., Tobena M., Sebio A., Gallano P., Barnadas A., Paez D. (2018) Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. BRIT J CLIN PHARMACO, 84 (6), 1389-1392.
IF: 3,8670
Ruiz-Pinto S., Pita G., Martin M., Alonso-Gordoa T., Barnes D.R., Alonso M.R., Herraez B., Garcia-Miguel P., Alonso J., Perez-Martinez A., Carton A.J., Gutierrez-Larraya F., Garcia-Saenz J.A., Benitez J., Easton D.F., Patino-Garcia A., Gonzalez-Neira A. (2018) Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. BREAST CANCER RES TR, 167 (1), 249-256.
IF: 3,4710
Sepulveda-Sanchez J.M., Munoz Langa J., Arraez M.A., Fuster J., Hernandez lain A., Reynes G., Rodriguez Gonzalez V., Vicente E., Vidal Denis M., Gallego O. (2018) SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). CLIN TRANSL ONCOL, 20 (1), 3-15.
IF: 2,4410
Serra-Aracil X., Pericay C., Golda T., Mora L., Targarona E., Delgado S., Reina A., Vallribera F., Enriquez-Navascues J.M., Serra-Pla S., Garcia-Pacheco J.C., Saigi E., Dotor E., Pisa A., Macias I., Pallisera A., Navarro S., Lacy A., Otero A., Biondo S., Golda T., Tarragona E., Hernandez P., Martinez M.C., Pernas J.C., Martin M., Gonzalez D., Paez D., Cusso X., Balague C., Coret M.J.G., Ferrer F.V., Andres B.D.S., Gallego A., Prieto H., Ramos J.L., Miramo J.J., Septiem J.G., Angulo F., Castillo J., Martin J.A., Seco I., Palazuelo C.M., Reina A., Rubio Gil F.A., Caro C., Varela R., Ramos M., Fernandez A., Belda R., Solbes R., Medina B., Reche P., Espin E., Vallribera F., Landolfini S., Capdevila J., Pascual M., Salvans S., Pera M., Diaz C., Barbadillo J.G., Palacios A., Pastor C.V., Pleguezuelo M., Trivino F., Martinez de Duenas J.L., Espana A.G., Rodriguez E.N., Trujillo R.L., Frangi A., Carmona M.D.R., Carrillo R.R., Gil M., Miranda V., Laso C.A., Lora P., Navascues J.M.E., Placer C., Borda N., la Casta A., Elosegui J.L., Saralegui Y., Guimon E., Mugica J.A., Plazas J.G., Arroyo A., Caro A., Millan M. (2018) Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). INT J COLORECTAL DIS, 33 (2), 241-249.
IF: 2,6410
Sharma P., Lopez-Tarruella S., Garcia-Saenz J.A., Khan Q.J., Gomez H.L., Prat A., Moreno F., Jerez-Gilarranz Y., Barnadas A., Picornell A.C., del Monte-Millan M., Gonzalez-Rivera M., Massarrah T., Pelaez-Lorenzo B., Palomero M.I., del Val R.G., Cortes J., Fuentes-Rivera H., Morales D.B., Marquez-Rodas I., Perou C.M., Lehn C., Wang Y.Y., Klemp J.R., Mammen J.V., Wagner J.L., Amin A.L., O'Dea A.P., Heldstab J., Jensen R.A., Kimler B.F., Godwin A.K., Martin M. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. CLIN CANCER RES, 24 (23), 5820-5829.
IF: 8,9110
Shepshelovich D., Tibau A., Goldvaser H., Molto C., Ocana A., Seruga B., Amir E. (2018) Postmarketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials. J CLIN ONCOL, 36 (18), 1798-1804.
IF: 28,2450